We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(Bloomberg) -- WuXi Biologics Cayman Inc. shares slumped for the second day as investors worried over a ramp-up in geopolitical tensions following a US draft bill targeting Chinese biotech companies.

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...

Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.

WuXi AppTec announced late yesterday that the Shanghai-based company had pared its stake in WuXi XDC Cayman through two block ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...